SSG
RARE icon

Summit Securities Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Summit Securities Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-192
Closed -$6.95K – 1367
2025
Q1 		$6.95K Buy
+192
New +$7.99K ﹤0.01% 581
2023
Q4 		– Sell
-657
Closed -$23K – 857
2023
Q3 		$23K Buy
+657
New +$26K ﹤0.01% 352
2014
Q4 		– Sell
-643
Closed -$36K – 708
2014
Q3 		$36K Buy
+643
New +$32.4K 0.01% 434

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Summit Securities Group's RARE Position: Q2 2025 in Review

Summit Securities Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 192 shares — an estimated $6.95K sold.

Summit Securities Group first reported a position in RARE in Q3 2014 and held it in 3 quarters. The position peaked at $36K in Q3 2014. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • Summit Securities Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 192 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $6.95K.
  • Summit Securities Group first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 3 quarters.
  • Summit Securities Group's Ultragenyx Pharmaceutical position peaked at $36K in Q3 2014.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.